{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037192","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.045021+00:00","generated_at":"2026-06-12T12:50:44.467561+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits","bullets":["Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).","clonoSEQ test volume +52% to 13,665 tests delivered.","Net loss $47.8M vs $52.1M YoY; adjusted EBITDA loss $24.8M vs $33.1M.","Full-year 2023 revenue guidance reiterated at $205-215M; operating expenses expected below 2022's $385.5M.","Nitin Sood, Chief Commercial Officer of MRD, resigns effective Aug 15; Susan Bobulsky assumes additional responsibilities, reports to CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037192","json":"https://secwatch.observer/filing/0000950170-23-037192.json","markdown":"https://secwatch.observer/filing/0000950170-23-037192.md","text":"https://secwatch.observer/filing/0000950170-23-037192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/adpt-20230728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T12:50:44.467561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d46295196d11785d393567386763b3360dd80be","claim":"Adaptive Biotechnologies Corp reported the quarter ended June 30, 2023 results: revenue $48.9 million, net income $47.8 million. Guidance reaffirmed.","evidence_excerpt":"Immune Medicine businesses and we remain committed to driving operational efficiencies across the company while supporting sustainable growth.” Recent Highlights • Revenue of $48.9 million for the second quarter 2023, representing 12% growth from $43.7 million in the second quarter 2022. • clonoSEQ test volume in the second quarter 2023 grew 52% to 13,665 tests","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$48.9 million"},{"label":"Net income","value":"$47.8 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a9f6b8c25a","claim":"Nitin Sood resigned as Chief Commercial Officer of the MRD business at Adaptive Biotechnologies Corp.","evidence_excerpt":"On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023037192/0000950170-23-037192-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Commercial Officer of the MRD business"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}